Literature DB >> 10606615

Anticancer drug targets: cell cycle and checkpoint control.

G I Shapiro1, J W Harper.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10606615      PMCID： PMC409893          DOI： 10.1172/JCI9054

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  41 in total

1.  Chemical inhibitors of cyclin-dependent kinases.

Authors:  L Meijer
Journal:  Trends Cell Biol       Date:  1996-10       Impact factor: 20.808

2.  Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

Authors:  A M Senderowicz; D Headlee; S F Stinson; R M Lush; N Kalil; L Villalba; K Hill; S M Steinberg; W D Figg; A Tompkins; S G Arbuck; E A Sausville
Journal:  J Clin Oncol       Date:  1998-09       Impact factor: 44.544

3.  Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27.

Authors:  Y Katayose; M Kim; A N Rakkar; Z Li; K H Cowan; P Seth
Journal:  Cancer Res       Date:  1997-12-15       Impact factor: 12.701

4.  Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells.

Authors:  K C Bible; S H Kaufmann
Journal:  Cancer Res       Date:  1996-11-01       Impact factor: 12.701

5.  Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.

Authors:  B Carlson; T Lahusen; S Singh; A Loaiza-Perez; P J Worland; R Pestell; C Albanese; E A Sausville; A M Senderowicz
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

6.  Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy.

Authors:  H Sedlacek; J Czech; R Naik; G Kaur; P Worland; M Losiewicz; B Parker; B Carlson; A Smith; A Senderowicz; E Sausville
Journal:  Int J Oncol       Date:  1996-12       Impact factor: 5.650

7.  Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4.

Authors:  L Stepanova; X Leng; S B Parker; J W Harper
Journal:  Genes Dev       Date:  1996-06-15       Impact factor: 11.361

8.  Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay.

Authors:  S N Powell; J S DeFrank; P Connell; M Eogan; F Preffer; D Dombkowski; W Tang; S Friend
Journal:  Cancer Res       Date:  1995-04-15       Impact factor: 12.701

9.  Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression.

Authors:  S P Frizelle; J Grim; J Zhou; P Gupta; D T Curiel; J Geradts; R A Kratzke
Journal:  Oncogene       Date:  1998-06-18       Impact factor: 9.867

10.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.

Authors:  N S Gray; L Wodicka; A M Thunnissen; T C Norman; S Kwon; F H Espinoza; D O Morgan; G Barnes; S LeClerc; L Meijer; S H Kim; D J Lockhart; P G Schultz
Journal:  Science       Date:  1998-07-24       Impact factor: 47.728
View more
  110 in total

1.  Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells.

Authors:  Kyu Kwang Kim; Thilo S Lange; Rakesh K Singh; Laurent Brard
Journal:  BMC Cancer       Date:  2010-02-25       Impact factor: 4.430

2.  Exposure of human lung cancer cells to 8-chloro-adenosine induces G2/M arrest and mitotic catastrophe.

Authors:  Hong-Yu Zhang; Yan-Yan Gu; Zeng-Gang Li; Yu-Hong Jia; Lan Yuan; Shu-Yan Li; Guo-Shun An; Ju-Hua Ni; Hong-Ti Jia
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

3.  Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs.

Authors:  M V Blagosklonny; R Robey; S Bates; T Fojo
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

4.  Expression of CD147 and Lewis y antigen in ovarian cancer and their relationship to drug resistance.

Authors:  Jian Gao; Zhenhua Hu; Juanjuan Liu; Dawo Liu; Yanyan Wang; Mingbo Cai; Danye Zhang; Mingzi Tan; Bei Lin
Journal:  Med Oncol       Date:  2014-04-02       Impact factor: 3.064

5.  Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.

Authors:  Edward Sausville; Patricia Lorusso; Michael Carducci; Judith Carter; Mary F Quinn; Lisa Malburg; Nilofer Azad; David Cosgrove; Richard Knight; Peter Barker; Sonya Zabludoff; Felix Agbo; Patricia Oakes; Adrian Senderowicz
Journal:  Cancer Chemother Pharmacol       Date:  2014-01-22       Impact factor: 3.333

Review 6.  Delivery of cell cycle genes to block astrocytoma growth.

Authors:  J Fueyo; C Gomez-Manzano; T J Liu; W K Yung
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

7.  Comparison of doxorubicin concentration profiles in radiofrequency-ablated rat livers from sustained- and dual-release PLGA millirods.

Authors:  Feng Qian; Nicholas Stowe; Gerald M Saidel; Jinming Gao
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

Review 8.  Family cancer syndromes: inherited deficiencies in systems for the maintenance of genomic integrity.

Authors:  Huferesh Darbary; Daniel L Stoler; Garth R Anderson
Journal:  Surg Oncol Clin N Am       Date:  2009-01       Impact factor: 3.495

9.  The radiosensitizer 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide induces DNA damage in EMT-6 mammary carcinoma cells.

Authors:  Joelle Haykal; Fady Geara; Makhluf J Haddadin; Colin A Smith; Hala Gali-Muhtasib
Journal:  Radiat Oncol       Date:  2009-07-14       Impact factor: 3.481

10.  Apoptotic and chemotherapeutic properties of iron (III)-salophene in an ovarian cancer animal model.

Authors:  Thilo S Lange; Carolyn McCourt; Rakesh K Singh; Kyu Kwang Kim; Ajay P Singh; Brian S Luisi; Onur Alptürk; Robert M Strongin; Laurent Brard
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.